BioLife Solutions, Inc. : BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board

New Members Include Key Opinion Leaders in Biobanking, Drug Discovery,
Regenerative Medicine Markets

Solutions Inc.(), a leading developer, manufacturer,marketer of proprietary media for cells, tissues,organs, today announced that three additional key opinion leaders in the , , (SAB). The new members are:

• John McMannis, Ph.D., Executive Vice President of Manufacturing at (ASX: MSB; OTC ADR: MBLTY). Dr. McMannis was previously the Director, Cellular Therapy Laboratory, Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.

• Jon Rowley, Ph.D., Innovation Director of Cell Processing Technologies at , responsible for driving technology developmentinnovation related to commercial scale bioprocessing of therapeutic .

Mike Rice, BioLife Chief Executive Officer, commented on the expansion of BioLife's SAB by stating, "We're thrilled that Drs. LeCluyse, McMannis,Rowley have joined our Scientific Advisory Board.  Each is a very highly thought of opinion leader in their respective fields.  We look forward to their contributions to our strategies for continually improving our quality environmentproductsservices offering."

These new members join the founding members of BioLife's SAB, who are:

• Lizabeth J. Cardwell, MT (ASCP), MBA, RAC, Compliance Consulting for Cell TherapyBiotechnology. Ms. Cardwell has provided Quality AssuranceRegulatory consulting for start-up cell therapybiotechnology companies since 2005. Prior to August 2005, Ms. Cardwell held the position of Director of Regulatory AffairsQuality Assurance at Xcyte Therapies.

• Colleen Delaney, M.D., is the Director of the Cord Blood ResearchTransplant Program at (FHCRC) (SCCA). She is an attending physician at Seattle Children's Hospital, Assistant Member of the Clinical Research Division of FHCRCAssistant Professor at the University of Washington School of Medicine.

• Dayong Gao, Ph.D., professor of biomedical engineering at the in Seattle. Dr. Gao has been actively engaged in cryopreservation research for more than 20 years, having authored over 130 peer-reviewed journal articles on cryopreservation.

• Shelly Heimfeld, Ph.D., is the Director, Heimfeld Research Laboratory, Scientific Director, Cellular Therapy Laboratory,Scientific Director, cGMP Therapeutic Manufacturing Facilities at the . Dr. Heimfeld is internationally recognized for research in hematopoietic-derived stem cellsthe development of cell processing technologies for improved cancer therapy.

• Andrew Hinson joined the Board in February 2007. He is currently the Vice President for ClinicalRegulatory Affairs for LoneStar Heart, Inc, a developer of proprietary biopolymer, small moleculecellular-based therapies to effectively treat heart failureother cardiac conditions. Mr. Hinson has diverse experience in the cellgene therapy marketsextensive experience with regulatoryclinical trial issues for new therapies for cardiac, neurologic,gastrointestinal applications.

• Darin Weber, Ph.D., is a leading regulatory expert for cellulartissue based products,a former FDA cellular therapy reviewer. He is currently the Executive Vice President, Global Regulatory Affairs at . Dr. Weber's knowledge of the regulatory landscape for cellgene therapy is extensivedirectly relevant to the Company's business since its biopreservation media products are a critical process component in numerous active clinical trials for new cellular therapy products.

• ,Laboratory Director of The Genesis Bank, a private umbilical cord blood bank. Dr. Woods is the current president of the Society for Cryobiology.

About BioLife Solutions

BioLife Solutions develops, manufacturesmarkets patented hypothermic storagecryopreservation solutions for cells, tissues,organs.  The Company's proprietary HypoThermosol®CryoStor® platform of solutions are marketed to academiccommercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery,toxicology testing. BioLife's products are serum-freeprotein-free, fully defined,are formulated to reduce preservation-induced, delayed-onset cell damagedeath.  BioLife's enabling technology provides academicclinical researchers significant improvements in post-thaw cell, tissue,organ viabilityfunction.  For more information please visit ,follow BioLife on .

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectationsbeliefsare subject to numerous risksuncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the SecuritiesExchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

# # # #

Media Relations:	Investor Relations:
Len Hall	Matt Clawson
Allen & Caron Inc	Allen & Caron Inc
[phone]	[phone]
[e-mail]	[e-mail]